Lymphomas News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

B ? Cell Lymphomas Pipeline Overview 2017 Market Insights and Epidemiology - Medgadget (blog)



B ? Cell Lymphomas Pipeline Overview 2017 Market Insights and Epidemiology 
Medgadget (blog)
RnRMarketResearch.com announces a new report ?B ? Cell Lymphomas Pipeline Insights, 2017? added to its Pharmaceuticals business research collection of its growing online library. ?B-Cell Lymphomas Pipeline Insights, 2017?, report provides ...

and more » 


Research may change how some prostate cancers, lymphomas are treated - The Charlottesville Newsplex



The Charlottesville Newsplex
 
Research may change how some prostate cancers, lymphomas are treated 
The Charlottesville Newsplex
CHARLOTTESVILLE, Va. (CBS19 NEWS) -- Researchers at the University of Virginia School of Medicine have learned that certain prostate cancers and lymphomas have a genetic weakness that can be exploited to help save lives. According to a release, the ...

and more » 


CAR T-cell therapy approved for B-cell lymphomas may save 'thousands of lives' in next few years - Healio



CAR T-cell therapy approved for B-cell lymphomas may save 'thousands of lives' in next few years 
Healio
The indication includes patients with diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL that arises from follicular lymphoma. The agent is not indicated for the treatment of patients with ...

and more » 


Varying Pertinence: MRD Testing Across Lymphomas - OncLive - OncLive



OncLive
 
Varying Pertinence: MRD Testing Across Lymphomas - OncLive 
OncLive
Michael L. Wang, MD, discusses the value of monitoring minimal residual disease across various lymphoid malignancies.

and more » 


Discovery suggests better way to treat certain prostate cancers ... - Medical Xpress



Medical Xpress
 
Discovery suggests better way to treat certain prostate cancers ... 
Medical Xpress
Certain prostate cancers and lymphomas have a major genetic weakness that doctors can exploit to help save patients' lives, researchers at the University of ...

and more » 


Adcetris Approved To Treat Most Common Cutaneous Lymphomas - Pharmacy Practice News



Pharmacy Practice News
 
Adcetris Approved To Treat Most Common Cutaneous Lymphomas 
Pharmacy Practice News
The FDA granted approval to brentuximab vedotin (BV) (Adcetris, Seattle Genetics) for the treatment of adults with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic ...
FDA Approves Adcetris for Lymphoma Subset - Cure Today Curetoday.com
FDA approves drug developed in Bothell to treat disfiguring blood cancer The Daily Herald
FDA Approves Adcentris for Anaplastic Large Cell Lymphoma Specialty Pharmacy Times
Business Wire (press release)  -OncLive 
all 13 news articles » 


Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017 - Lymphoma News Today



Bayer to Present Long-term Results of Aliqopa in Treating Indolent Lymphomas at ASH 2017 
Lymphoma News Today
?Updated analyses based on a data cut-off of Feb 2017 reaffirmed the robust efficacy (ORR of 58.5% and median DOR >1 year [duration of response]) of copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma,? the researchers ...

 


New targeting approach to treat T-cell lymphomas published - EPM ... - EPM Magazine



EPM Magazine
 
New targeting approach to treat T-cell lymphomas published - EPM ... 
EPM Magazine
Clinical-stage biopharmaceutical company, Autolus has announced the publication of an article detailing a unique targeting strategy for the treatment of patients ...
Unique approach to treatment of rare and aggressive blood cancers Medical Xpress

all 3 news articles » 


Poor Outcomes in Elderly Patients After Treatment Failure in B-Cell Lymphomas - Cancer Network



Poor Outcomes in Elderly Patients After Treatment Failure in B-Cell Lymphomas 
Cancer Network
A study examining treatment and outcome patterns following failure of initial treatment for B-cell lymphoma found that rituximab can improve outcomes regardless of which initial therapy was used, but elderly patients, including those treated with an R ...

 


Prescient Therapeutics: PTX-100 To Target Rhoa-Mutant Lymphomas - Investing.com



Prescient Therapeutics: PTX-100 To Target Rhoa-Mutant Lymphomas 
Investing.com
Prescient Therapeutics Ltd (AX:PTX) is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib ...